Gastroelectric stimulation for influencing pancreatic secretions

• US 7,076,306 B2
• Filed: 07/26/2004
• Issued: 07/11/2006
• Est. Priority Date: 12/03/1999
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Marchal, Benoit, Starkebaum, Warren
• Primary Examiner(s): Bockelman, Mark
• Application Number:
  US10/749,595
• Publication Number:
  US 20050033375A1
• Time in Patent Office: 715 Days
• Field of Search: 607/40, 607/2
• US Class Current: 607/40
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362

Abstract

A gastroelectric stimulator comprises a neurostimulator for producing a stimulation signal, at least one electrical lead, and at least two electrical contacts. The electrical lead has a proximal end and a distal end, the proximal end being connected to the neurostimulator and the distal end positionable in a lead position within the patient'"'"'s abdomen. The electrodes are carried near the electrical lead distal end. The electrodes are electrically connected through the electrical lead to the neurostimulator to receive the stimulation signal and convey this signal to an electrode position within the patient'"'"'s digestive system. The stimulation signal is adapted to influence pancreatic secretions.

Claims

1. A method for decreasing pancreatic exocrine secretions in a patient, comprising:

applying at least two electrodes to a digestive system of the patient that are coupled by at least one lead to a neurostimulator;

stimulating the digestive system with a stimulation signal generated by the neurostimulator and conveyed through the lead to the electrode contacting the digestive system

wherein the digestive system stimulation is transmitted to a pancreas of a patient, and

wherein pancreatic exocrine secretion is decreased by the digestive system stimulation.

2. The method of claim 1 wherein at least one of the electrodes contacts a stomach.

3. The method of claim 2, wherein the electrode contacts a stomach pacemaker region.

4. The method of claim 1 wherein at least one of the electrodes contacts an intestine.

5. The method of claim 1, wherein the signal has a frequency greater than 6,000 pulses per minute.

6. The method of claim 1, wherein the stimulation signal has a pulse width in the range from about 0.01 mSec to 500 mSec.

7. The method of claim 1, wherein the stimulation signal has a peak amplitude in the range from about 0.01 mA to 100.0 mA.

8. The method of claim 1, further comprising measuring a patient condition and controlling the stimulation signal in response to the measured patient condition.

9. The method of claim 8 wherein measuring the patient condition is accomplished with a sensor electrically connected to a neurostimulator.

10. The method of claim 8 wherein measuring the patient condition is accomplished by a person.